Aminah Jatoi, M.D

Betty J. Foust, MD and Parents' Professor of Oncology, Mayo Clinic, Rochester, Minnesota

Aminah Jatoi, M.D. is Professor of Oncology at the Betty J. Foust, M.D. and Parents’ Professor of Oncology at Mayo Clinic in Minnesota, where she primarily cares for patients with gastrointestinal and gynecological malignancies. Her research focuses on supportive care issues in cancer patients. The author of 300+ publications, she seeks to mitigate side effects from the cancer treatment, anxiety related to the cancer and to cancer treatment, and distressing signs and symptoms related to the cancer itself with a special emphasis on such research in older patients with cancer. Her research has been funded by National Cancer Institute and various foundations. She also serves on the editorial boards for the Journal of Clinical Oncology; American Journal of Hospice and Palliative Medicine; Current Opinion in Supportive and Palliative Care; Journal of Cachexia, Sarcopenia and Muscle; Journal of Cancer Education, Journal of Geriatric Oncology, and the Mayo Clinic Proceedings. In addition to her clinical and research activities, Dr. Jatoi is active in education. She has been recognized with several teaching awards, including Teacher of the Year. She is the director and principal investigator on a Mayo Clinic junior faculty training program funded by the National Cancer Institute and provides mentorship to many residents, fellows and junior faculty.

Dr. Richard Dunne

Associate Professor of Medicine & Section Leader, GI Oncology, Wilmot Cancer Institute and The University of Rochester Medical Center

Dr. Richard Dunne is an Associate Professor of Medicine and is the Section Leader of GI Oncology at the Wilmot Cancer Institute and The University of Rochester Medical Center. His research is focused on furthering our understanding of the mechanisms and effects of Cancer Cachexia and the development of novel therapeutics in this space. His work is supported by the U.S. National Cancer Institute and Cancer Research UK. He is the study chair and PI for the U.S. Nationwide observational LOTUS trial, which seeks to develop a new classification system for Cancer Cachexia and update current definitions.

Dr. Rony Dev

Associate Professor, Department of Palliative Care and Rehabilitation Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.

Dr. Rony Dev is an Associate Professor in the Department of Palliative Care and Rehabilitation Medicine, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center, Houston, Texas. He is board certified in Internal Medicine and Palliative Care. Dr. Dev provides palliative care consultation regarding pain and symptom management for patients with cancer. He is the Director of the Nutrition Rehabilitation and Cachexia Clinic. His research interests include symptom management including the treatment of anorexia-cachexia syndrome, improving communication in family meetings for patients with cancer and their caregivers, and interventions to improve adaptive coping mechanisms for critically ill patients. He has published in numerous journals regarding screening for malnutrition in ambulatory supportive care clinics, treatments for anorexia and cancer cachexia, and the management of hormonal abnormalities including hypovitaminosis D in patients with cancer. He received the Young Investigator's Award, MASCC 2009, International Symposium, and is a member of the American Society of Clinical Oncology and American Academy of Hospice and Palliative Medicine. He is the section editor for Symptoms for PC-FACS for Journal of Pain and Symptom Management and an Editorial Board member for Annals of Palliative Medicine.

Professor Jeffrey Crawford

George Barth Geller Professor Emeritus for Research in Cancer, Department of Medicine, Duke University Medical Center

Professor Jeffrey Crawford MD is a graduate of Ohio Wesleyan University and Ohio State University School of Medicine. He completed his training in internal medicine and hematology oncology at Duke University. Over his career at Duke, Dr Crawford has served as clinical director of the thoracic oncology program, chief of the division of medical oncology, and associate director for clinical research for the Duke Cancer Institute. Dr Crawford has had a long term commitment to National Cancer Institute clinical trials, and has served in a number of leadership positions within Cancer and Leukemia Group B and the Alliance. He is currently a member of the executive committee and board of directors for the Alliance Foundation. Dr Crawford’s research has been in clinical trials in lung cancer with a focus on supportive care. He has published more than 250 articles. His expertise includes the role of hematopoietic growth factors for the management of chemotherapy induced myelosuppression, as well as the study of novel agents for cancer cachexia.